RYDAPT is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Novartis via or
online through the patient safety information (PSI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370
or by email at

RYDAPT can make extended survival a reality in patients with newly diagnosed FLT3+ disease

Watch the RATIFY clinical trial video here:


Provide a targeted treatment option for your FLT3+ AML patients

Watch Professor Schlenk on the importance of FLT3 testing here:


RYD20-C019 | August 2020

© Hartley Taylor - Website design and maintenance: Byte Sized Solutions